Back to library
Loading…
cells · Journal of Clinical Oncology · 2023
This study reports on a phase 1/2 clinical trial evaluating the safety and efficacy of pexidartinib, a CSF-1R inhibitor, in patients with advanced solid tumours and tenosynovial giant cell tumour.
Uhm JH, Jones RL, Ravi V, et al.
This study reports on a phase 1/2 clinical trial evaluating the safety and efficacy of pexidartinib, a CSF-1R inhibitor, in patients with advanced solid tumours and tenosynovial giant cell tumour.